What FDA's Drug Shortage Database Is, and How a Drug Gets On It

Answer first: it is a national judgment

FDA maintains a public database of drugs it has determined to be in shortage in the United States. The list is national, and every entry on it reflects a judgment about the country rather than a report about a pharmacy.

The agency states the standard it applies. It considers a drug to be in shortage when, on a nationwide level, supply is not meeting current demand, or supply is not forecast to meet projected demand.

That framing explains most of the confusion around the list. A drug can be genuinely hard to get in your town while the national supply is adequate, and the database will say nothing about your town at all.

The definition underneath the list

The statutory definition is short. A drug shortage is a period of time when the demand or projected demand for the drug within the United States exceeds the supply of the drug.

Two words in it do most of the work. Projected means the assessment is partly forward-looking, so a drug can enter shortage before shelves empty. And within the United States means the market being measured is a national one.

FDA describes how it reaches the determination. It receives and reviews input from manufacturers, patients, health care providers and others, including compounders, then evaluates supply and demand at the nationwide level.

The agency also says where most of that input comes from. Most information is provided by manufacturers, which is worth holding in mind when reading any single entry.

How information reaches FDA, through two separate doors

Manufacturers and applicants report through one channel, an industry portal. FDA describes it as intended only for drug manufacturers and applicants, and says industry can notify the agency there about new discontinuances, manufacturing quality issues, increases in product demand, recalls, supply interruptions and other events.

Everyone else uses a different door. FDA runs a public portal for patients, health care providers and organizations to report a new shortage that is not already listed.

The agency sets out the order of operations. Check the database first by generic name or active ingredient. If the drug is already listed, talk to a provider or pharmacist about options, because FDA is already working on it. Report through the public portal only if it is not there.

There is a third path for a shortage already on the list. Patients, providers and organizations may submit information about the status of an existing shortage by email to the drug shortage staff.

FDA explains why local reports matter even when they are not national. When it receives them, it contacts manufacturers to confirm whether available supply will meet national demand, and says advance notice sometimes helps prevent or shorten a shortage.

The seven reasons an entry may give

Each listing states a reason, and the available reasons are fixed rather than free text. FDA says that under section 506E of the Federal Food, Drug, and Cosmetic Act and its own regulations, seven reasons may be cited for a particular shortage.

They are requirements related to complying with good manufacturing practices, regulatory delay, shortage of an active ingredient, and shortage of an inactive ingredient component. The remaining three are discontinuation of the manufacture of the drug, delay in shipping of the drug, and demand increase for the drug.

FDA also says which of these is most common. Manufacturing quality issues are the most common reason for drug shortages, ahead of production delays and delays receiving raw materials and components from suppliers.

A reason code is a category, not an explanation. Two shortages citing the same code can have very little in common beyond which box they fell into.

What each entry actually contains

FDA describes the fields on the list. It includes the names and National Drug Code numbers for the drugs, the name of each applicant, the reason for the shortage as determined by FDA, and the estimated duration.

There is also a therapeutic category label, and FDA warns against over-reading it. The designation describes labeled indications and populations where the drug is commonly used, does not indicate approved status, and a drug may sit in more than one category.

Individual products are broken down by presentation, and this is where the fine print matters most. FDA states that all of the presentation information posted under individual product shortages is provided by the manufacturer and can change daily.

So the database mixes two kinds of statement. The determination that a shortage exists is FDA's. Much of the detail beneath it is the manufacturer's, and the page says so.

The status words, and the one that is not a determination

Four status terms carry defined meanings. Currently in Shortage means demand or projected demand within the United States exceeds supply.

Resolved means FDA has determined that supply is no longer exceeded by demand or projected demand. That is an agency conclusion, and it is the one with legal consequences attached elsewhere.

Discontinuation reflects a manufacturer's notification that it is permanently stopping production of a covered drug. FDA states that the discontinuations listed in the database reflect information received from manufacturers and are for informational purposes only.

Available is the term most easily misread. FDA says a status of available reflects the most current information from the manufacturer, but is not an FDA determination that the shortage has been resolved. Available and resolved are different claims by different parties.

How a drug leaves the list, and how long the record stays

A drug comes off the shortage list when FDA determines that supply is no longer exceeded by demand or projected demand. The agency updates the list daily with new and resolved shortages, along with additional information from suppliers about manufacturing capacity.

The entry does not vanish immediately. FDA states that resolved shortages remain on the webpage for six months, and discontinued products remain for one year.

That retention window is useful and easy to misuse. A resolved entry visible today is a record of a shortage that has ended, not evidence of one continuing.

After those windows pass, the entry leaves the page entirely. An absence from the list is therefore ambiguous on its own, because it covers both a drug that was never listed and one whose retention period has run out.

What FDA can do while a drug is listed, and what it cannot

The agency describes real levers. It works with firms on manufacturing and quality problems, and may exercise regulatory discretion where that mitigates significant risk to patients.

It can expedite review. Alternative manufacturers often need new production lines or new raw material sources approved, and FDA says it can and does expedite those reviews to help resolve shortages of medically necessary drugs.

It can extend dating. Where a firm holds inventory near or past expiry and has data supporting an extension, FDA can review that and determine an extended expiration date is supportable. The agency publishes a separate list of extended use dates for that purpose.

It can look abroad. Where a US manufacturer cannot resolve a shortage of a medically necessary drug, FDA may seek an FDA-registered foreign manufacturer willing to redirect foreign-approved product into the US market. It evaluates the formulation, other attributes and the quality of the manufacturing site first.

And there is a hard limit the agency states twice. FDA cannot require a firm to increase production, and cannot require a firm to keep making a drug it wants to discontinue.

There is more than one shortage list

FDA is not the only publisher. The agency notes that the American Society of Health-System Pharmacists also maintains a drug shortage website, and says that while both provide shortage information, there are some differences between them.

FDA points readers to its own comparison of the two rather than treating them as interchangeable. That is a signal in itself: two lists can disagree about the same drug on the same day without either being wrong on its own terms.

Shortages outside the drug center go elsewhere again. Biological products, including blood and vaccines, are handled by a different center with its own page and its own reporting address.

So a claim that something is or is not in shortage should name which list it came from. Without that, the claim is not checkable.

What this settles, and what it does not

The database settles a national question. It tells you whether FDA has determined that supply is not meeting demand across the country for a specific product and presentation.

It does not settle your pharmacy. FDA says local supply problems are usually temporary and often involve distribution issues that resolve once the pharmacy can reorder from its distributor.

It also does not price anything. The agency states that pricing issues are not within its purview and points people toward the Federal Trade Commission on that subject.

The practical use is narrow and real. Look the drug up by generic name or active ingredient, read the status word carefully, notice whether the detail beneath it is FDA's or the manufacturer's, and check the date you are reading it on.